Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

By H. Ford, M. Bourlière, S. Gordon, S. Flamm, C. Cooper, A. Ramji, M. Tong, N. Ravendhran, J. Vierling, T. Tran and 23 more. New England Journal of Medicine, 2017

625 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/4d7dafa06cf8cafa1de4381ecf88108691ac719e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. M. Puoti
5. X. Forns
6. J. Pawlotsky

Citations in the corpus

• EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, methodology): “Two phase III trials, POLARIS-1 and POLARIS-4, demonstrated the safety and efficacy of the triple combination of sofosbuvir, velpatasvir and voxilaprevir for 12 weeks in patients who failed to achieve SVR with a DAA-based regimen, including patients exposed to protease and/or NS5A inhibitors.(35) PO”
• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, methodology): “Two phase III trials, POLARIS-1 and POLARIS-4, demonstrated the safety and efficacy of the triple combination of sofosbuvir, velpatasvir and voxilaprevir for 12 weeks in patients who failed to achieve SVR with a DAA-based regimen, including patients exposed to protease and/or NS5A inhibitors.(265) I”